Viveve Medical Q2 2022 Earnings Results & Report

Viveve Medical EPS Results

• Actual EPS: -$0.67
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 6 of last 8 quarters

Viveve Medical Revenue Results

• Actual Revenue: $1.80 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Viveve Medical (NASDAQ:VIVE) was a women’s health company focused on developing and commercializing noninvasive treatments for vaginal health. Its principal product was the Viveve System, a medical device that used cryogen-cooled monopolar radiofrequency energy to heat and remodel tissue. The company promoted the system primarily for the treatment of vaginal laxity and related intimate-health concerns.

The Viveve System was designed for use by healthcare professionals in office-based procedures and incorporated a disposable treatment tip. Viveve Medical sought regulatory clearances and commercial adoption in the United States and international markets, with distribution and clinical use reported in multiple countries.

The company operated under the name Viveve, Inc. before adopting the Viveve Medical name. Publicly available information about its later operations, leadership, and current commercial activities is limited, and the company’s status and product availability may have changed since its period of public trading under the symbol VIVE.